Pantoprazole-d6
(Synonyms: BY1023-d6; SKF96022-d6) 目录号 : GC45539
An internal standard for the quantification of pantoprazole
Cas No.:922727-65-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pantoprazole-d6 is intended for use as an internal standard for the quantification of pantoprazole by GC- or LC-MS. Pantoprazole is a proton pump inhibitor that inhibits H+/K+-ATPase activity in porcine gastric membrane vesicles with an IC50 value of 6.8 μM.1 It reduces basal gastric acid secretion in pylorus-ligated rats (ED50 = 1.3 mg/kg) and inhibits mepirizole-induced increases in gastric acid secretion in an anesthetized rat model of gastric fistula (ED50 = 0.8 mg/kg).2 Pantoprazole inhibits formation of mepirizole-induced duodenal lesions in rats (ED50 = 0.5 mg/kg). Formulations containing pantoprazole have been used in the treatment of gastroesophageal reflux disease (GERD) and hypersecretory conditions, including Zollinger-Ellison Syndrome.
References
1. Beil, W., Staar, U., and Sewing, K.F. Pantoprazole: A novel H+/K+-ATPase inhibitor with an improved pH stability. Eur. J. Pharmacol. 218(2-3), 265-271 (1992).
2. Takeuchi, K., Konaka, A., Nishijima, M., et al. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole. J. Gastroenterol. Hepatol. 14(3), 251-257 (1999).
| Cas No. | 922727-65-9 | SDF | |
| 别名 | BY1023-d6; SKF96022-d6 | ||
| Canonical SMILES | O=S(CC(N=CC=C1OC([2H])([2H])[2H])=C1OC([2H])([2H])[2H])C2=NC3=CC(OC(F)F)=CC=C3N2 | ||
| 分子式 | C16H9D6F2N3O4S | 分子量 | 389.4 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5681 mL | 12.8403 mL | 25.6805 mL |
| 5 mM | 0.5136 mL | 2.5681 mL | 5.1361 mL |
| 10 mM | 0.2568 mL | 1.284 mL | 2.5681 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。